Annual Cash & Cash Equivalents
$1.38 B
-$831.97 M-37.69%
December 1, 2024
Summary
- As of February 25, 2025, GMAB annual cash & cash equivalents is $1.38 billion, with the most recent change of -$831.97 million (-37.69%) on December 1, 2024.
- During the last 3 years, GMAB annual cash & cash equivalents has risen by +$11.78 million (+0.86%).
- GMAB annual cash & cash equivalents is now -37.69% below its all-time high of $2.21 billion, reached on December 31, 2023.
Performance
GMAB Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$1.38 B
+$425.44 M+44.79%
December 1, 2024
Summary
- As of February 25, 2025, GMAB quarterly cash and cash equivalents is $1.38 billion, with the most recent change of +$425.44 million (+44.79%) on December 1, 2024.
- Over the past year, GMAB quarterly cash and cash equivalents has increased by +$425.44 million (+44.79%).
- GMAB quarterly cash and cash equivalents is now -37.69% below its all-time high of $2.21 billion, reached on December 31, 2023.
Performance
GMAB Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
GMAB Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -37.7% | +44.8% |
| 3 y3 years | +0.9% | +44.8% |
| 5 y5 years | +158.3% | +44.8% |
GMAB Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -37.7% | +0.9% | -37.7% | +121.2% |
| 5 y | 5-year | -37.7% | +158.3% | -37.7% | +158.3% |
| alltime | all time | -37.7% | >+9999.0% | -37.7% | >+9999.0% |
Genmab A/S Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $1.38 B(-37.7%) | $1.38 B(+44.8%) |
| Sep 2024 | - | $949.92 M(+52.8%) |
| Jun 2024 | - | $621.72 M(-70.7%) |
| Mar 2024 | - | $2.12 B(-3.9%) |
| Dec 2023 | $2.21 B(+55.0%) | $2.21 B(+9.2%) |
| Sep 2023 | - | $2.02 B(+27.4%) |
| Jun 2023 | - | $1.59 B(-11.8%) |
| Mar 2023 | - | $1.80 B(+26.3%) |
| Dec 2022 | $1.42 B(+4.4%) | $1.42 B(+3.8%) |
| Sep 2022 | - | $1.37 B(-0.5%) |
| Jun 2022 | - | $1.38 B(+1.2%) |
| Mar 2022 | - | $1.36 B(-0.2%) |
| Dec 2021 | $1.36 B(+13.6%) | $1.36 B(+0.1%) |
| Sep 2021 | - | $1.36 B(-10.2%) |
| Jun 2021 | - | $1.52 B(+21.9%) |
| Mar 2021 | - | $1.24 B(+3.7%) |
| Dec 2020 | $1.20 B(+125.3%) | $1.20 B(-14.4%) |
| Sep 2020 | - | $1.40 B(+40.7%) |
| Jun 2020 | - | $996.40 M(+21.7%) |
| Mar 2020 | - | $818.62 M(+53.7%) |
| Dec 2019 | $532.52 M(+552.2%) | $532.52 M(-21.7%) |
| Sep 2019 | - | $680.39 M(+666.2%) |
| Jun 2019 | - | $88.80 M(-49.8%) |
| Mar 2019 | - | $176.85 M(+116.6%) |
| Dec 2018 | $81.65 M(-62.4%) | $81.65 M(-41.4%) |
| Sep 2018 | - | $139.42 M(-17.3%) |
| Jun 2018 | - | $168.64 M(+6.6%) |
| Mar 2018 | - | $158.17 M(-27.2%) |
| Dec 2017 | $217.16 M(+397.4%) | $217.16 M(+26.3%) |
| Sep 2017 | - | $171.97 M(+8.4%) |
| Jun 2017 | - | $158.71 M(+44.5%) |
| Mar 2017 | - | $109.81 M(+151.5%) |
| Dec 2016 | $43.66 M | $43.66 M(-63.6%) |
| Sep 2016 | - | $119.90 M(+25.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2016 | - | $95.95 M(-0.6%) |
| Mar 2016 | - | $96.53 M(-24.6%) |
| Dec 2015 | $128.02 M(+118.4%) | $128.02 M(+45.3%) |
| Sep 2015 | - | $88.13 M(+59.7%) |
| Jun 2015 | - | $55.20 M(+15.9%) |
| Mar 2015 | - | $47.63 M(-18.8%) |
| Dec 2014 | $58.63 M(+88.4%) | $58.63 M(+26.5%) |
| Sep 2014 | - | $46.33 M(-35.6%) |
| Jun 2014 | - | $71.97 M(-41.7%) |
| Mar 2014 | - | $123.49 M(+296.8%) |
| Dec 2013 | $31.12 M(+162.1%) | $31.12 M(-5.2%) |
| Sep 2013 | - | $32.81 M(+2.9%) |
| Jun 2013 | - | $31.90 M(+46.7%) |
| Mar 2013 | - | $21.75 M(+83.2%) |
| Dec 2012 | $11.87 M(+4.5%) | $11.87 M(-83.3%) |
| Sep 2012 | - | $71.00 M(+234.6%) |
| Jun 2012 | - | $21.22 M(+5.6%) |
| Mar 2012 | - | $20.09 M(+76.8%) |
| Dec 2011 | $11.36 M(-36.9%) | $11.36 M(-62.3%) |
| Sep 2011 | - | $30.11 M(+67.7%) |
| Jun 2011 | - | $17.96 M(-6.4%) |
| Mar 2011 | - | $19.19 M(+6.6%) |
| Dec 2010 | $18.01 M(-79.7%) | $18.01 M(-76.2%) |
| Sep 2010 | - | $75.76 M(+6.0%) |
| Jun 2010 | - | $71.44 M(+46.9%) |
| Mar 2010 | - | $48.64 M(-45.1%) |
| Dec 2009 | $88.62 M(+574.5%) | $88.62 M |
| Dec 2008 | $13.14 M(-49.0%) | - |
| Dec 2007 | $25.77 M(-66.0%) | - |
| Dec 2006 | $75.89 M(+25.5%) | - |
| Dec 2005 | $60.49 M(-20.8%) | - |
| Dec 2004 | $76.38 M(+46.2%) | - |
| Dec 2003 | $52.25 M(+46.3%) | - |
| Dec 2002 | $35.71 M | - |
FAQ
- What is Genmab A/S annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Genmab A/S?
- What is Genmab A/S annual cash & cash equivalents year-on-year change?
- What is Genmab A/S quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Genmab A/S?
- What is Genmab A/S quarterly cash and cash equivalents year-on-year change?
What is Genmab A/S annual cash & cash equivalents?
The current annual cash & cash equivalents of GMAB is $1.38 B
What is the all time high annual cash & cash equivalents for Genmab A/S?
Genmab A/S all-time high annual cash & cash equivalents is $2.21 B
What is Genmab A/S annual cash & cash equivalents year-on-year change?
Over the past year, GMAB annual cash & cash equivalents has changed by -$831.97 M (-37.69%)
What is Genmab A/S quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of GMAB is $1.38 B
What is the all time high quarterly cash and cash equivalents for Genmab A/S?
Genmab A/S all-time high quarterly cash and cash equivalents is $2.21 B
What is Genmab A/S quarterly cash and cash equivalents year-on-year change?
Over the past year, GMAB quarterly cash and cash equivalents has changed by +$425.44 M (+44.79%)